| Literature DB >> 31683926 |
Michela Deiana1,2, Giovanni Malerba3, Luca Dalle Carbonare4, Samuele Cheri5,6, Cristina Patuzzo7, Grygoriy Tsenov8, Lucas Moron Dalla Tor9, Antonio Mori10, Gianantonio Saviola11, Donato Zipeto12, Federico Schena13, Monica Mottes14, Maria Teresa Valenti15.
Abstract
Osteoarthritis (OA) is predominantly characterized by the progressive degradation of articular cartilage, the connective tissue produced by chondrocytes, due to an imbalance between anabolic and catabolic processes. In addition, physical activity (PA) is recognized as an important tool for counteracting OA. To evaluate PA effects on the chondrocyte lineage, we analyzed the expression of SOX9, COL2A1, and COMP in circulating progenitor cells following a half marathon (HM) performance. Therefore, we studied in-depth the involvement of metabolites affecting chondrocyte lineage, and we compared the metabolomic profile associated with PA by analyzing runners' sera before and after HM performance. Interestingly, this study highlighted that metabolites involved in vitamin B6 salvage, such as pyridoxal 5'-phosphate and pyridoxamine 5'-phosphate, were highly modulated. To evaluate the effects of vitamin B6 in cartilage cells, we treated differentiated mesenchymal stem cells and the SW1353 chondrosarcoma cell line with vitamin B6 in the presence of IL1β, the inflammatory cytokine involved in OA. Our study describes, for the first time, the modulation of the vitamin B6 salvage pathway following PA and suggests a protective role of PA in OA through modulation of this pathway.Entities:
Keywords: SOX9; cartilage; metabolomics; osteoarthritis; physical activity; vit.B6
Mesh:
Substances:
Year: 2019 PMID: 31683926 PMCID: PMC6912200 DOI: 10.3390/cells8111374
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600
Relative expression (in percent) of cluster differentiation (CD) obtained by depletion method in PRE and POST run CPCs.
| Cluster Differentiation Transcript | Pre Run (%) | Post Run (%) | |
|---|---|---|---|
| CD105 | 68 ± 0.3 | 67 ± 0.4 | 0.2 |
| CD73 | 73 ± 0.2 | 72 ± 0.3 | 0.06 |
| CD3 | 0 | 0 | NA * |
| CD14 | 0.5 ± 0.07 | 0.6 ± 0.08 | 0.12 |
| CD19 | 0 | 0 | NA * |
| CD45 | 1.6 ± 0.3 | 1.8 ± 0.3 | 0.06 |
| CD34 | Low levels | Low levels | NA * |
* NA, not available.
Figure 1Chondrogenic transcription factor SOX9, as well as COL2A1 and COMP, were upregulated (fold of gene expression >1) in CPCs collected after the run (POST) * p ≤ 0.05 vs. PRE.
Figure 2Cloud plot of the metabolomics modulated features (fold change ≥ 1.5, p-value ≤ 0.05). Feature signals belonging to molecules defined by m/z and retention time. Differential analysis based on the intensity of the signals in PRE versus POST run sera. Green and red circles represent the upregulated and downregulated features, respectively. The size value of each circle corresponds to (log) fold change. Color shades are used to represent the p-value, with brighter circles indicating lower p-values. The retention time corrected (TIC) total ion chromatograms are overlaid in gray in the figure background.
Figure 3Modulated metabolites between PRE and POST run athletes. The t-test was considered as significant only for features with an adjusted p-value ≤0.05 (red circles).
List of significantly modulated metabolites.
| Name | Nominal | Log2fold | Modulation (Up/Down) | |
|---|---|---|---|---|
| Pyridoxamine 5′-phosphate | 0.0003 | 0.0000072958 | 5.4 | UP |
| Lipoic acid. reduced | 0.0003 | 0.0000076800 | −1.56 | DOWN |
| Pyridoxal 5′-phosphate | 0.0006 | 0.0000000104 | 4.1 | UP |
| dUMP | 0.0007 | 0.0000192660 | 5.93 | UP |
| 4.4-dimethylzymosterol | 0.004 | 0.0000397850 | 2.72 | UP |
| 1.3-Dimethyl-8-phenylxanthine | 0.012 | 0.0000458276 | 7.16 | UP |
| Phosphatidylinositol-3.4.5-trisphosphate | 0.017 | 0.0000662191 | 1.56 | UP |
| 4α-formyl-4β-methyl-5α-cholesta-8.24-dien-3β-ol | 0.019 | 0.0000815126 | −4.94 | DOWN |
| 8-oxo-dGTP | 0.049 | 0.0000930718 | −1.79 | DOWN |
Pathways identified by highly modulated metabolites between PRE run and POST run sera.
| Pathway | All Metabolites | Overlapping Metabolites | ||
|---|---|---|---|---|
| Pyrimidine deoxyribonucleotides biosynthesis from CTP | 2 | 2 | 0.0094 | 0.0361 |
| Pyridoxal 5-phosphate salvage | 4 | 2 | 0.031 | 0.1164 |
| Zymosterol biosynthesis | 5 | 2 | 0.05 | 0.244 |
Figure 4The most significantly modulated terms suggested by metabolomic analysis between the two groups.
Figure 5Vitamin B6 (100 µM) increased the expression levels of the chondrogenic transcription factor SOX9 (A) and of COMP (B) in both MSC and SW1353 cell lines; * p ≤ 0.05 vs. controls.
Figure 6The presence of 1 ng/mL IL1β caused an increase of the inflammatory factor COX2 gene expression and reduced SOX9 and COMP genes expression during chondrogenic differentiation. Vitamin B6 supplement (100 µM) was able to revert IL1β effects on MSCs during chondrogenic differentiation. * p ≤ 0.05, (* CTRL vs. IL1β, * CTRL vs. IL1β+ Vit B6, * IL1β vs. IL1β+ Vit B6).
Figure 7(A) Senescence-associated beta-galactosidase staining was increased in SW1353 cells treated with IL1β (b) compared to controls (a); vitamin B6′s supplementation counteracted IL1β-induced senescence (c). (B) The generation of ROS induced by IL1β in SW1353 was reduced by adding vitamin B6 in cells medium. (C) Similarly, vitamin B6′s supplementation (c) was able to reduce IL1β-induced apoptosis (b) in SW1353 cells. (D) The increased COX2 gene expression and the reduced expression of chondrogenic genes due to IL1β treatment were reverted thanks to vitamin B6 supplementation. (E) Vitamin B6 ability in counteracting IL1β effects in SW1353 was confirmed by Alcian blue staining evaluating GAG production: (a) Controls; (b) IL1β treated; (c) IL1β + vit B6 treated; magnifications: A: 5X (Well plate) and 10X (culture slides); C: 20X; E: 5X; * p ≤ 0.05; *** p ≤ 0.0005; **** p ≤ 0.000005. ( CTRL vs. IL1β, * IL1β vs. IL1β+ Vit B6).